Eli Lilly's oral GLP-1 drug Foundayo (orforglipron) has been authorized in the UK for both obesity and type 2 diabetes, its first European approval. The drug has also been selected for a priority health technology assessment in England for weight management.
Geo Focus
Coverage Attributes:
Beta
Informative:
53
%
Data Driven:
17
%
Interviews Q&as:
9
%
Promotional:
6
%
Opinion:
6
%
Themes Covered:
Not enough data
Pitching Insights
Eliza Slawther's articles predominantly focus on legal policy regulation and government announcements within the healthcare and pharmaceutical industry. Her coverage revolves around institutions such as EMA (European Medicines Agency) and FDA (Food and Drug Administration), with a specific emphasis on drug development, AI regulation, and their impacts.
Given her emphasis on government announcements and regulatory developments in the pharma industry, she would likely be interested in pitches from experts who can provide analysis or commentary about new regulations, policies, or major decisions made by these agencies. Sources well-versed in the workings of EMA, FDA, drug approval processes or AI applications in healthcare are likely to attract her attention.
As Eliza's geographic focus is not specified but given the nature of her coverage related to European agencies like EMA along with global entities like FDA suggests an international outlook for potential stories.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Journalists With Similar Coverage:
Based on similarity of content.
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
